Identification of CD4+ and CD8+ T cell epitopes of woodchuck hepatitis virus core and surface antigens in BALB/c mice

Vaccine

Volumn 28, Issue 32, 2010, Pages 5323-5331

  Ochoa Callejero, L ^a   Otano, I ^a   Vales, A ^a   Olague C ^a   Sarobe, P ^a   Lasarte, J J ^a   Prieto, J ^a   Menne, S ^b   Gonzalez Aseguinolaza G ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b Department of Obstetrics Gynecology   (United States)

Author keywords

Chronic hepatitis infection; DNA vaccine; Hepatitis B virus; T cell epitopes; Woodchuck hepatitis virus

Indexed keywords

ALANYLTYROSYLGLYCYLASPARTYLPROLYLPHENYLALANYLTHREONYLTHREONYLLEUCINE; ASPARTYLPHENYLALANYLPHENYLALANYLPROLYLASPARTYLLEUCYLASPARAGINYLALANYLLEUCYLVALINE; CD4 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; EPITOPE; FREUND ADJUVANT; GAMMA INTERFERON; GLYCYLPHENYLALANYLVALYLASPARTYLGLYCYLLEUCYLARGINYLASPARTYLLEUCINE; HLA ANTIGEN; LEUCYLPROLYLLEUCYLASPARTYLPHENYLALANYLPHENYLALANYLASPARTYLLEUCINE; METHIONYLTYROSYLLEUCYLARGINYLARGINYLPHENYLALANYLISOLEUCYLISOLEUCINE; NANOPARTICLE; PHENYLALANYLLEUCYLPROLYLLEUCYLASPARTYLPHENYLALANYLPHENYLALANYLPROLYLASPARTYLLEUCYLASPARAGINYLALANYLLEUCYLVALYLASPARTIC ACID; POLYETHYLENEIMINE; SERYLTYROSYLGLUTAMINYLLEUCYLLEUCYLASPARAGINYLPHENYLALANYLLEUCYLPROLYLLEUCINE; TRYPTOPHANYLGLYCYLPROLYLALANYLLEUCYLLEUCYLSERYLISOLEUCYLLEUCINE; UNCLASSIFIED DRUG; VALYLTYROSYLPHENYLALANYLLEUCYLTRYPTOPHANYLTHREONYLLYSYLISOLEUCYLLEUCINE; VIRUS ANTIGEN; VIRUS VACCINE; WOODCHUCK HEPATITIS VIRUS CORE ANTIGEN; WOODCHUCK HEPATITIS VIRUS SURFACE ANTIGEN; CORE PROTEIN; H2 ANTIGEN; HEPATITIS ANTIGEN; MEMBRANE ANTIGEN;

ANTIGEN PRESENTING CELL; ARTICLE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA IMMUNIZATION; DRUG SYNTHESIS; FEMALE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING; SPLEEN CELL; WOODCHUCK HEPATITIS VIRUS; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CELLULAR IMMUNITY; EPITOPE MAPPING; IMMUNOLOGY;

ANIMALS; ANTIGENS, SURFACE; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; FEMALE; H-2 ANTIGENS; HEPATITIS ANTIGENS; HEPATITIS B VIRUS, WOODCHUCK; IMMUNITY, CELLULAR; MICE; MICE, INBRED BALB C; VIRAL CORE PROTEINS;

EID: 77954951631     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.05.043     Document Type: Article

References (39)

1. World Health Organization. Department of communicable diseases surveillance and response, WHO/CDS/CSR/LYO, ; 2002. http://www.who.int/emc.
2. Zanetti A.R., Van Damme P., Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 2008, 26(49):6266-6273.
3. Lok A.S. Navigating the maze of hepatitis B treatments. Gastroenterology 2007, 132:1586-1594.
4. Bertoletti A., Gehring A.J. The immune response during hepatitis B virus infection. J Gen Virol 2006, 87:1439-1449.
5. Michel M.L., Polb S., Brechotc C., Tiollais P. Immunotherapy of chronic hepatitis B by anti HBV vaccine: from present to future. Vaccine 2001, 19(March (17-19)):2395-2399.
6. Gonzalez-Aseguinolaza G., Crettaz J., Ochoa L., Otano I., Aldabe R., Paneda A. Gene therapy for viral hepatitis. Expert Opin Biol Ther 2006, 6(12):1263-1278.
7. Roggendorf M., Tolle T.K. The woodchuck: an animal model for hepatitis B virus infection in man. Intervirology 1995, 38(1-2):100-112.
8. Menne S., Tennant B.C. Unraveling hepatitis B virus infection of mice and men (and woodchucks and ducks). Nat Med 1999, 5(10):1125-1126.
9. Feitelson M.A., Marion P.L., Robinson W.S. Antigenic and structural relationships of the surface antigens of hepatitis B virus, ground squirrel hepatitis virus, and woodchuck hepatitis virus. J Virol 1981, 39(2):447-454.
10. Galibert F., Chen T.N., Mandart E. Nucleotide sequence of a cloned woodchuck hepatitis virus genome: comparison with the hepatitis B virus sequence. J Virol 1982, 41(1):51-65.
11. Kodama K., Ogasawara N., Yoshikawa H., Murakami S. Nucleotide sequence of a cloned woodchuck hepatitis virus genome: evolutional relationship between hepadnaviruses. J Virol 1985, 56(December (3)):978-986.
12. Korba B.E., Cote P., Hornbuckle W., Tennant B.C., Gerin J.L. Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans. Hepatology 2000, 31(5):1165-1175.
13. Menne S., Cote P.J. The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection. World J Gastroenterol 2007, 13(1):104-124.
14. Yang D.L., Lu M., Hao L.J., Roggendorf M. Molecular cloning and characterization of major histocompatibility complex class I cDNAs from woodchuck (Marmota monax). Tissue Antigens 2000, 55(6):548-557.
15. Zhou J.H., Ferencik S., Rebmann V., Yang D.L., Lu M., Roggendorf M., et al. Molecular genetic and biochemical analysis of woodchuck (Marmota monax) MHC class I polymorphism. Tissue Antigens 2003, 61(3):240-248.
16. Menne S., Maschke J., Tolle T.K., Lu M., Roggendorf M. Characterization of T-cell response to woodchuck hepatitis virus core protein and protection of woodchucks from infection by immunization with peptides containing a T-cell epitope. J Virol 1997, 71(January (1)):65-74.
17. Gujar S.A., Michalak T.I. Flow cytometric quantification of T cell proliferation and division kinetics in woodchuck model of hepatitis B. Immunol Invest 2005, 34(2):215-236.
18. Frank I., Budde C., Fiedler M., Dahmen U., Viazov S., Lu M., et al. Acute resolving woodchuck hepatitis virus (WHV) infection is associated with a strong cytotoxic T-lymphocyte response to a single WHV core peptide. J Virol 2007, 81(13):7156-7163.
19. Garzon M.R., Berraondo P., Crettaz J., Ochoa L., Vera M., Lasarte J.J., et al. Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex. Vaccine 2005, 23(11):1384-1392.
20. Sarobe P., Jauregui J.I., Lasarte J.J., Garcia N., Civeira M.P., Borras-Cuesta F., et al. Production of interleukin-2 in response to synthetic peptides from hepatitis C virus E1 protein in patients with chronic hepatitis C: relationship with the response to interferon treatment. J Hepatol 1996, 25(1):1-9.
21. Bertoletti A., Chisari F.V., Penna A., Guilhot S., Galati L., Missale G., et al. Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein. J Virol 1993, 67(4):2376-2380.
22. Penna A., Chisari F.V., Bertoletti A., Missale G., Fowler P., Giuberti T., et al. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 1991, 174(6):1565-1570.
23. Lopez D., Samino Y., Koszinowski U.H., Del Val M. HIV envelope protein inhibits MHC class I presentation of a cytomegalovirus protective epitope. J Immunol 2001, 167(8):4238-4244.
24. Menne S., Tennant B.C., Gerin J.L., Cote P.J. Chemoimmunotherapy of chronic hepatitis B virus infection in the woodchuck model overcomes immunologic tolerance and restores T-cell responses to pre-S and S regions of the viral envelope protein. J Virol 2007, (19):10614-10624.
25. Kaech S.M., Wherry E.J., Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2002, 2(4):251-262.
26. Sette A.D., Oseroff C., Sidney J., Alexander J., Chesnut R.W., Kakimi K., et al. Overcoming T cell tolerance to the hepatitis B virus surface antigen in hepatitis B virus-transgenic mice. J Immunol 2001, 166(2):1389-1397.
27. Guidotti L.G., Chisari F.V. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001, 19:65-91.
28. Guidotti L.G., Chisari F.V. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006, 1:23-61.
29. Brusic V., Petrovsky N., Zhang G., Bajic V.B. Prediction of promiscuous peptides that bind HLA class I molecules. Immunol Cell Biol 2002, 80:280-285.
30. Riedl P., Wieland A., Lamberth K., Buus S., Lemonnier F., Reifenberg K., et al. Elimination of immunodominant epitopes from multispecific DNA-based vaccines allows induction of CD8 T cells that have a striking antiviral potential. J Immunol 2009, 183(1):370-380.
31. Livingston B.D., Crimi C., Fikes J., Chesnut R.W., Sidney J., Sette A. Immunization with the HBV core 18-27 epitope elicits CTL responses in humans expressing different HLA-A2 supertype molecules. Hum Immunol 1999, 60(11):1013-1017.
32. Wentworth P.A., Celis E., Crimi C., Stitely S., Hale L., Tsai V., et al. In vitro induction of primary, antigen-specific CTL from human peripheral blood mononuclear cells stimulated with synthetic peptides. Mol Immunol 1995 Jun, 32(9):603-612.
33. Heathcote J., McHutchison J., Lee S., Tong M., Benner K., Minuk G., et al. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology 1999, 30(August (2)):531-536.
34. Vitiello A., Ishioka G., Grey H.M., Rose R., Farness P., LaFond R., et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 1995, 95(January (1)):341-349.
35. Livingston B.D., Crimi C., Grey H., Ishioka G., Chisari F.V., Fikes J., et al. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. J Immunol 1997, 159(August (3)):1383-1392.
36. Schirmbeck R., Fissolo N., Chaplin P., Reimann J. Enhanced priming of multispecific, murine CD8+ T cell responses by DNA vaccines expressing stress protein-binding polytope peptides. J Immunol 2003, 171(3.):1240-1246.
37. Davis H.L., Schirmbeck R., Reimann J., Whalen R.G. DNA-mediated immunization in mice induces a potent MHC class I-restricted cytotoxic T lymphocyte response to the hepatitis B envelope protein. Hum Gene Ther 1995, 6(November (11)):1447-1456.
38. Wieland A., Riedl P., Reimann J., Schirmbeck R. Silencing an immunodominant epitope of hepatitis B surface antigen reveals an alternative repertoire of CD8 T cell epitopes of this viral antigen. Vaccine 2009, 28(December (1)):114-119.
39. Tolle T.K., Glebe D., Linder M., Linder D., Schmitt S., Geyer R., et al. Structure and glycosylation patterns of surface proteins from woodchuck hepatitis virus. J Virol 1998, 72(December (12)):9978-9985.